Efficacy and safety of major ozonated autohemotherapy in the treatment of ischemic stroke: a meta-analysis_Chinese Journal of Evidence-Based Medicine

Authors：

LI Jingwen ^1,2,3 , ZHANG Na ^1,2,3 , GU Qinghong ^2,3 , LI Jieyun ^2,3 , GUO Kangle ^1,2,3 , LI Meixuan ^1,2,3 , LI Yanfei ^1,2,3 , ZHANG Hairong ¹ , ZHANG Yunqi ¹ , LIU Xingrong ¹ , BAI Fei ⁴ ,  LI Xiuxia ^1,2,3 ,  YANG Kehu ^1,2,3

1. Evidence-Based Social Science Research Center, Health Technology Assessment Center, School of Public Health, Lanzhou University, Lanzhou 730000, P.R.China;
2. Evidence-Based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou 730000, P.R.China;
3. Evidence-Based Social Science Research Center of Lanzhou University, School of Public Health, Lanzhou University, Lanzhou 730000, P.R.China;
4. Guidance Center for Medical Management Services of the National Health Commission, Beijing 100044, P.R.China;

Corresponding?author：

LI Xiuxia, Email: lixiuxia@lzu.edu.cn; YANG Kehu, Email: kehuyangebm2006@126.com

Keywords：

Major ozonated autohemotherapy; Ischemic stroke; Systematic review; Meta-analysis; Randomized controlled trial

DOI：

10.7507/1672-2531.202011034

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To systematically review the efficacy and safety of major ozonated autohemotherapy in the treatment of ischemic stroke.Methods PubMed, EMbase, The Cochrane Library, Web of Science, CBM, WanFang Data, VIP and CNKI were electronically searched to collect randomized controlled trials (RCTs) of the efficacy and safety of major ozonated autohemotherapy in the treatment of ischemic stroke from inception to July 1^st, 2020. Two reviewers independently screened literature, extracted data and assessed risk of bias of included studies. Meta-analysis was then performed by using RevMan 5.3 software.Results A total of 25 RCTs involving 3 681 patients were included. The results of meta-analysis showed that the major ozonated autohemotherapy combined with conventional therapy in the treatment of patients with ischemic stroke in terms of total effective rate (RR=1.20, 95%CI 1.15 to 1.25, P<0.001), national institutes of health stroke scale (MD=?3.15, 95%CI ?4.72 to ?1.59, P<0.001), total cholesterol (MD=?1.00, 95%CI ?1.48 to ?0.53, P<0.001), triglyceride (MD=?0.74, 95%CI ?1.04 to ?0.43, P<0.001), low-density lipoprotein cholesterol (MD=?0.65, 95%CI ?1.22 to ?0.09, P=0.02), and activity of daily living (MD=11.97, 95%CI 4.48 to 19.47, P=0.002) were superior to the conventional treatment group. There was no significant difference between the two groups in high-density lipoprotein cholesterol (MD=0.25, 95%CI ?0.46 to 0.96, P=0.49) and the incidence of adverse effects (OR=3.15, 95%CI 0.93 to 10.63, P=0.06).Conclusions The major ozonated autohemotherapy can significantly improve the prognosis of patients with ischemic stroke while not affecting the adverse effects. Due to the limited quality and quantity of the included studies, more high-quality studies are needed to verify the above conclusions.

Citation： LI Jingwen, ZHANG Na, GU Qinghong, LI Jieyun, GUO Kangle, LI Meixuan, LI Yanfei, ZHANG Hairong, ZHANG Yunqi, LIU Xingrong, BAI Fei, LI Xiuxia, YANG Kehu. Efficacy and safety of major ozonated autohemotherapy in the treatment of ischemic stroke: a meta-analysis. Chinese Journal of Evidence-Based Medicine, 2021, 21(8): 889-897. doi: 10.7507/1672-2531.202011034 Copy

1.	GBD 2017 Causes of Death Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, 2018, 392(10159): 1736-1788.
2.	陳偉偉, 高潤霖, 劉力生, 等. 《中國心血管病報告 2017》概要. 中國循環雜志, 2018, 33(1): 1-8.
3.	GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, 2015, 385(9963): 117-171.
4.	國家衛生和計劃生育委員會. 中國衛生和計劃生育統計年鑒 2017. 北京: 中國協和醫科大學出版社, 2018.
5.	吳亞哲, 陳偉偉. 中國腦卒中流行概況. 心腦血管病防治, 2016, 16(6): 410-414.
6.	中華醫學會神經病學分會中華醫學會神經病學分會腦血管病學組. 中國急性缺血性腦卒中診治指南 2018. 中華神經科雜志, 2018, 51(9): 666-682.
7.	Saver JL, Fonarow GC, Smith EE, et al. Time to treatment with intravenous tissue plasminogen activator and outcome from acute ischemic stroke. JAMA, 2013, 309(23): 2480-2488.
8.	Ng SH, Wong AWK, Chen CH, et al. Stroke factors associated with thrombolysis use in hospitals in Singapore and us: a cross-registry comparative study. Cerebrovasc Dis, 2019, 47(5-6): 291-298.
9.	孟文婷, 李東翔, 佟玲. 缺血性腦卒中的治療研究進展. 中國新藥雜志, 2016, 25(10): 1114-1120.
10.	陶希, 黃靚, 蔡華安, 等. 臭氧氧化與缺血再灌注損傷的研究進展. 中國康復理論與實踐, 2016, 22(12): 1420-1424.
11.	胡俊橋. 醫用三氧臨床應用研究進展. 實用中醫藥雜志, 2017, 33(2): 211-213.
12.	中華醫學會麻醉學分會疼痛學組中國醫師協會麻醉醫師分會中國民族醫藥學會疼痛分會三氧學組. 三氧自體血療法專家共識. 轉化醫學雜志, 2018, 7(6): 326-328, 345.
13.	楊克虎. 循證社會科學的產生, 發展與未來. 圖書與情報, 2018, (3): 1-10.
14.	Zhang J, Li Y, Zhang B, et al. Evidence-based traditional Chinese medicine research: Beijing declaration. J Evid Based Med, 2020, 13(2): 91-92.
15.	中國神經科學會, 中華神經外科學會. 各類腦血管疾病診斷要點(1995). 臨床和實驗醫學雜志, 2013, 12(7): 559.
16.	Ni X, Lin H, Li H, et al. Evidence-based practice guideline on integrative medicine for stroke 2019. J Evid Based Med, 2020, 13(2): 137-152.
17.	Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions (version 5.1.0). The Cochrane Collaboration, 2011. Available at: http://www.cochrane-handbook.org.
18.	Wu XN, Zhang T, Wang J, et al. Magnetic resonance diffusion tensor imaging following major ozonated autohemotherapy for treatment of acute cerebral infarction. Neural Regen Res, 2016, 11(7): 1115-1121.
19.	包穎, 陳曉虹, 姜海濤. 臭氧大自血療法聯合辛伐他汀對缺血性卒中患者血脂水平的影響. 中風與神經疾病雜志, 2011, 28(4): 353-354.
20.	陳敏. 臭氧自血療法輔助治療急性腦梗死的療效觀察. 吉林: 吉林大學, 2014.
21.	崔小妮. 臭氧(O3)自體血回輸聯合常規方法治療急性腦梗塞的效果分析. 臨床醫學研究與實踐, 2018, 3(5): 26-27.
22.	鄧美杰. 用醫用臭氧自血療法對老年缺血性腦卒中患者進行治療的效果探析. 當代醫藥論叢, 2018, 16(19): 44-45.
23.	黃雁, 趙煥寧, 王揚廣. 臭氧自血療法對急性腦梗塞療效及對血液相關指標的影響. 右江民族醫學院學報, 2010, 32(4): 511-512.
24.	郭明遠, 陳建平, 郭媛媛, 等. 臭氧大自血療法治療急性缺血性腦梗死患者的臨床療效評估. 現代生物醫學進展, 2016, 16(23): 4475-4477, 4515.
25.	李寒姝, 裴梓峰, 潘薇, 等. 三氧自體血回輸療法對急性腦梗死患者血脂的作用分析. 當代醫學, 2018, 24(36): 116-118.
26.	李輝, 湯永紅. 臭氧自血回輸在急性腦梗死患者中的應用研究. 現代醫藥衛生, 2015, 31(12): 1836-1837.
27.	寧顯武. 探討免疫三氧自血回輸治療急性腦梗死患者的臨床效果. 世界最新醫學信息文摘(連續型電子期刊), 2016, 17(71): 360.
28.	覃翠, 李賢. 藥物聯合臭氧大自血治療急性腦梗死的療效觀察. 中西醫結合心血管病電子雜志, 2016, 4(31): 197-198.
29.	劉曉燕. 臭氧自體血回輸治療急性腦梗死臨床觀察. 廣州: 廣州中醫藥大學, 2010.
30.	陶東霞, 王璐, 馬蘭, 等. 臭氧自體血回輸療法治療急性腦梗死的療效分析. 中國醫科大學學報, 2017, 46(9): 860-861.
31.	王莉娟. 臭氧自體血回輸治療急性腦梗死對患者血脂的影響. 中外女性健康研究, 2017, (2): 136-137.
32.	劉丹, 蘇丙賀, 趙春陽, 等. 臭氧大自血療法對急性腦梗死的臨床應用分析. 世界最新醫學信息文摘(電子版), 2013, (11): 114-115.
33.	王生鋒. 免疫三氧血回輸療法治療 170 例急性腦梗死的臨床療效. 中國醫藥科學, 2014, 4(10): 158-160.
34.	吳娜. 臭氧自體血回輸治療急性腦梗死的臨床分析. 中國醫藥指南, 2017, 15(4): 25-26.
35.	王昕, 張月秋, 王俊清, 等. 高壓臭氧大自血治療腦梗死臨床觀察. 中國保健營養: 臨床醫學學刊, 2009, 18(7): 276-277.
36.	徐家萍, 郭愛紅, 徐巧絨. 臭氧自體血回輸療法對急性期腦梗死患者腦功能重塑的影響. 臨床醫學研究與實踐, 2019, 4(5): 15-16.
37.	武肖娜, 彭凱潤, 楊紅軍, 等. 臭氧自體血回輸治療對急性腦梗死患者血脂的影響. 中國實用神經疾病雜志, 2013, 16(7): 34-36.
38.	楊繼群, 黃紅麗, 代龍玉. 臭氧自血療法輔助治療急性期腦梗死的療效和安全性研究. 黑龍江醫學, 2020, 44(3): 310-313.
39.	楊改清, 胥麗霞. 疏血通注射液聯合臭氧治療腦梗死臨床研究. 河南中醫, 2015, 35(3): 525-528.
40.	周鳳坤, 明少鵬, 楊立強. 臭氧大自血自體回輸療法在腦梗死急性期中的應用. 中國醫藥導報, 2017, 14(5): 59-62.
41.	鄒仁林, 薛彬, 郭靜, 等. 醫用三氧大自血療法治療急性腦梗死的臨床觀察. 中國實用內科雜志, 2018, 38(S2): 50-53.
42.	尹月, 王林, 王慧婕. 臭氧大自體血回輸治療急性腦梗死的臨床療效評估. 神經損傷與功能重建, 2016, 11(1): 93-94.
43.	中華醫學會神經病學分會, 中華醫學會神經病學分會腦血管病學組, 中華醫學會神經病學分會神經血管介入協作組. 中國急性缺血性腦卒中早期血管內介入診療指南 2018. 中華神經科雜志, 2018, 51(9): 683-691.
44.	Powers WJ, Rabinstein AA, Ackerson T, et al. Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke, 2019, 50(12): e344-e418.
45.	楊海蕾, 陳晨, 屈秋民. 社區腦卒中高危人群頸動脈粥樣硬化與缺血性腦卒中的關系. 西安交通大學學報(醫學版), 2019, 40(6): 916-921.
46.	路旭. 氫氯吡格雷聯合尤瑞克林治療高齡腦梗死的療效及對神經功能缺損和血液流變學的影響. 中國實用神經疾病雜志, 2014, 17(9): 22-24.
47.	Shi YL, Miao RZ, Cheng L, et al. Up-regulation of T-lymphoma and metastasis gene 1 in gastric cancer and its involvement in cell invasion and migration. Chin Med J, 2013, 126(4): 640-645.
48.	彭芳華. 高壓臭氧治療高脂血癥的臨床研究. 中國保健營養, 2018, 28(26): 95.
49.	Zanardi I, Borrelli E, Valacchi G, et al. Ozone: a multifaceted molecule with unexpected therapeutic activity. Curr Med Chem, 2016, 23(4): 304-314.

1. GBD 2017 Causes of Death Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, 2018, 392(10159): 1736-1788.
2. 陳偉偉, 高潤霖, 劉力生, 等. 《中國心血管病報告 2017》概要. 中國循環雜志, 2018, 33(1): 1-8.
3. GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, 2015, 385(9963): 117-171.
4. 國家衛生和計劃生育委員會. 中國衛生和計劃生育統計年鑒 2017. 北京: 中國協和醫科大學出版社, 2018.
5. 吳亞哲, 陳偉偉. 中國腦卒中流行概況. 心腦血管病防治, 2016, 16(6): 410-414.
6. 中華醫學會神經病學分會中華醫學會神經病學分會腦血管病學組. 中國急性缺血性腦卒中診治指南 2018. 中華神經科雜志, 2018, 51(9): 666-682.
7. Saver JL, Fonarow GC, Smith EE, et al. Time to treatment with intravenous tissue plasminogen activator and outcome from acute ischemic stroke. JAMA, 2013, 309(23): 2480-2488.
8. Ng SH, Wong AWK, Chen CH, et al. Stroke factors associated with thrombolysis use in hospitals in Singapore and us: a cross-registry comparative study. Cerebrovasc Dis, 2019, 47(5-6): 291-298.
9. 孟文婷, 李東翔, 佟玲. 缺血性腦卒中的治療研究進展. 中國新藥雜志, 2016, 25(10): 1114-1120.
10. 陶希, 黃靚, 蔡華安, 等. 臭氧氧化與缺血再灌注損傷的研究進展. 中國康復理論與實踐, 2016, 22(12): 1420-1424.
11. 胡俊橋. 醫用三氧臨床應用研究進展. 實用中醫藥雜志, 2017, 33(2): 211-213.
12. 中華醫學會麻醉學分會疼痛學組中國醫師協會麻醉醫師分會中國民族醫藥學會疼痛分會三氧學組. 三氧自體血療法專家共識. 轉化醫學雜志, 2018, 7(6): 326-328, 345.
13. 楊克虎. 循證社會科學的產生, 發展與未來. 圖書與情報, 2018, (3): 1-10.
14. Zhang J, Li Y, Zhang B, et al. Evidence-based traditional Chinese medicine research: Beijing declaration. J Evid Based Med, 2020, 13(2): 91-92.
15. 中國神經科學會, 中華神經外科學會. 各類腦血管疾病診斷要點(1995). 臨床和實驗醫學雜志, 2013, 12(7): 559.
16. Ni X, Lin H, Li H, et al. Evidence-based practice guideline on integrative medicine for stroke 2019. J Evid Based Med, 2020, 13(2): 137-152.
17. Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions (version 5.1.0). The Cochrane Collaboration, 2011. Available at: http://www.cochrane-handbook.org.
18. Wu XN, Zhang T, Wang J, et al. Magnetic resonance diffusion tensor imaging following major ozonated autohemotherapy for treatment of acute cerebral infarction. Neural Regen Res, 2016, 11(7): 1115-1121.
19. 包穎, 陳曉虹, 姜海濤. 臭氧大自血療法聯合辛伐他汀對缺血性卒中患者血脂水平的影響. 中風與神經疾病雜志, 2011, 28(4): 353-354.
20. 陳敏. 臭氧自血療法輔助治療急性腦梗死的療效觀察. 吉林: 吉林大學, 2014.
21. 崔小妮. 臭氧(O3)自體血回輸聯合常規方法治療急性腦梗塞的效果分析. 臨床醫學研究與實踐, 2018, 3(5): 26-27.
22. 鄧美杰. 用醫用臭氧自血療法對老年缺血性腦卒中患者進行治療的效果探析. 當代醫藥論叢, 2018, 16(19): 44-45.
23. 黃雁, 趙煥寧, 王揚廣. 臭氧自血療法對急性腦梗塞療效及對血液相關指標的影響. 右江民族醫學院學報, 2010, 32(4): 511-512.
24. 郭明遠, 陳建平, 郭媛媛, 等. 臭氧大自血療法治療急性缺血性腦梗死患者的臨床療效評估. 現代生物醫學進展, 2016, 16(23): 4475-4477, 4515.
25. 李寒姝, 裴梓峰, 潘薇, 等. 三氧自體血回輸療法對急性腦梗死患者血脂的作用分析. 當代醫學, 2018, 24(36): 116-118.
26. 李輝, 湯永紅. 臭氧自血回輸在急性腦梗死患者中的應用研究. 現代醫藥衛生, 2015, 31(12): 1836-1837.
27. 寧顯武. 探討免疫三氧自血回輸治療急性腦梗死患者的臨床效果. 世界最新醫學信息文摘(連續型電子期刊), 2016, 17(71): 360.
28. 覃翠, 李賢. 藥物聯合臭氧大自血治療急性腦梗死的療效觀察. 中西醫結合心血管病電子雜志, 2016, 4(31): 197-198.
29. 劉曉燕. 臭氧自體血回輸治療急性腦梗死臨床觀察. 廣州: 廣州中醫藥大學, 2010.
30. 陶東霞, 王璐, 馬蘭, 等. 臭氧自體血回輸療法治療急性腦梗死的療效分析. 中國醫科大學學報, 2017, 46(9): 860-861.
31. 王莉娟. 臭氧自體血回輸治療急性腦梗死對患者血脂的影響. 中外女性健康研究, 2017, (2): 136-137.
32. 劉丹, 蘇丙賀, 趙春陽, 等. 臭氧大自血療法對急性腦梗死的臨床應用分析. 世界最新醫學信息文摘(電子版), 2013, (11): 114-115.
33. 王生鋒. 免疫三氧血回輸療法治療 170 例急性腦梗死的臨床療效. 中國醫藥科學, 2014, 4(10): 158-160.
34. 吳娜. 臭氧自體血回輸治療急性腦梗死的臨床分析. 中國醫藥指南, 2017, 15(4): 25-26.
35. 王昕, 張月秋, 王俊清, 等. 高壓臭氧大自血治療腦梗死臨床觀察. 中國保健營養: 臨床醫學學刊, 2009, 18(7): 276-277.
36. 徐家萍, 郭愛紅, 徐巧絨. 臭氧自體血回輸療法對急性期腦梗死患者腦功能重塑的影響. 臨床醫學研究與實踐, 2019, 4(5): 15-16.
37. 武肖娜, 彭凱潤, 楊紅軍, 等. 臭氧自體血回輸治療對急性腦梗死患者血脂的影響. 中國實用神經疾病雜志, 2013, 16(7): 34-36.
38. 楊繼群, 黃紅麗, 代龍玉. 臭氧自血療法輔助治療急性期腦梗死的療效和安全性研究. 黑龍江醫學, 2020, 44(3): 310-313.
39. 楊改清, 胥麗霞. 疏血通注射液聯合臭氧治療腦梗死臨床研究. 河南中醫, 2015, 35(3): 525-528.
40. 周鳳坤, 明少鵬, 楊立強. 臭氧大自血自體回輸療法在腦梗死急性期中的應用. 中國醫藥導報, 2017, 14(5): 59-62.
41. 鄒仁林, 薛彬, 郭靜, 等. 醫用三氧大自血療法治療急性腦梗死的臨床觀察. 中國實用內科雜志, 2018, 38(S2): 50-53.
42. 尹月, 王林, 王慧婕. 臭氧大自體血回輸治療急性腦梗死的臨床療效評估. 神經損傷與功能重建, 2016, 11(1): 93-94.
43. 中華醫學會神經病學分會, 中華醫學會神經病學分會腦血管病學組, 中華醫學會神經病學分會神經血管介入協作組. 中國急性缺血性腦卒中早期血管內介入診療指南 2018. 中華神經科雜志, 2018, 51(9): 683-691.
44. Powers WJ, Rabinstein AA, Ackerson T, et al. Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke, 2019, 50(12): e344-e418.
45. 楊海蕾, 陳晨, 屈秋民. 社區腦卒中高危人群頸動脈粥樣硬化與缺血性腦卒中的關系. 西安交通大學學報(醫學版), 2019, 40(6): 916-921.
46. 路旭. 氫氯吡格雷聯合尤瑞克林治療高齡腦梗死的療效及對神經功能缺損和血液流變學的影響. 中國實用神經疾病雜志, 2014, 17(9): 22-24.
47. Shi YL, Miao RZ, Cheng L, et al. Up-regulation of T-lymphoma and metastasis gene 1 in gastric cancer and its involvement in cell invasion and migration. Chin Med J, 2013, 126(4): 640-645.
48. 彭芳華. 高壓臭氧治療高脂血癥的臨床研究. 中國保健營養, 2018, 28(26): 95.
49. Zanardi I, Borrelli E, Valacchi G, et al. Ozone: a multifaceted molecule with unexpected therapeutic activity. Curr Med Chem, 2016, 23(4): 304-314.

Chinese Journal of Evidence-Based Medicine

Efficacy and safety of major ozonated autohemotherapy in the treatment of ischemic stroke: a meta-analysis

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content